Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block) * Patients must have PTEN gene mutation/deletion * There must be evidence of PTEN expression by immunohistochemistry (IHC) (any amount of staining will be considered positive for expression) * Patients with complete loss of PTEN by IHC, regardless of PTEN mutations/deletion status, will be enrolled into MATCH subprotocol EAY131-P, not this subprotocol (EAY131-N) * Patients must have hemoglobin \>= 9 g/dL * Patients must have a serum creatinine that =\< 1.5 x upper limit of normal (ULN) or have a 24-hour creatinine clearance of \>= 50 mL/min Exclusion Criteria: * Patients must not have known hypersensitivity to GSK2636771 or compounds of similar chemical or biologic composition. * Patients must not have tumors harboring co-existing aberrations activating the PI3K/MTOR and MAPK pathways, such as PIK3CA, PIK3R1, BRAF, KRAS and AKT1, TSC1/2, mTOR, NF2, NRAS, HRAS, NF1 * Patients must not have received prior treatment with agents targeting the PI3K beta, AKT, or mTOR pathways: * This includes (but is not limited to): * mTOR inhibitors: temsirolimus, everoli…